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Summary
Background Chemokines and their receptors could play key roles in the recruitment of T cells
to the asthmatic lung. CCR8 is preferentially expressed on T-helper type 2 cells, and is thought
to play a role in the pathogenesis of human asthma.
Objective Determine the expression of CCR8 on Tcells in blood, bronchoalveolar lavage (BAL)
and bronchial mucosa from asthmatics and normal subjects.
Methods CCR8 expression in blood and BAL from asthma and normal subjects was studied
using ﬂow cytometry. CCR8 expression on IFN-g
1 and IL-4
1/IL-13
1 blood and BAL T cells
was studied following stimulation with Phorbol–Myristate–Acetate and Calcium Ionophore.
Parafﬁn-embedded bronchial biopsies were used to study CCR8 in bronchial epithelium.
Results The percentage of CD3
1 cells expressing CCR8 in the blood was higher in asthmatics
(4.7 0.4%) compared with normal subjects (3.0 0.4%; Po0.01).There was an approximately
sixfold enrichment of CCR8 on IL-4
1/IL-13
1 cells compared with IFN-g
1 Tcells (Po0.001) in
both asthmatic and normal subjects in both blood and BAL. Signiﬁcantly more BAL T cells
expressed CCR8 in asthmatic (8.6 0.8%) compared with normal subjects (3.9 0.7%)
(Po0.01). In paired blood-BAL samples from asthmatics, signiﬁcantly more CCR81CD3
1 T
cells were present in BAL (9.0 0.9%) than in blood (5.6 0.9%; Po0.05). There were more
CCR8-positive cells in bronchial biopsies from asthmatic (93 11cells/mm
2) compared with
normal subjects (30 16cells/mm
2)( Po0.05). The ligand CCL1 was increased in the BAL of
asthmatics compared with normal subjects (35 6 vs. 12.9 7pg/mL; Po0.05).
Conclusion There maybe arole for CCR8 in the recruitment of Tcells tothe lung in asthmatics.
Keywords asthma, CCR8, chemokine receptor, lung T cell
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Introduction
Asthma is a disease characterized by chronic inﬂamma-
tion of the airways [1]. Tcells are thought to play a crucial
role in initiating and maintaining this inﬂammatory
process [2–7]. Within the family of T cells are a number
of subsets covering a wide range of functions. A T-helper
type 2(TH2) predominant inﬂammatory process initiated
through the cytokines IL-4, IL-5, IL-9 and IL-13 is thought
to be central to asthma pathophysiology [8–11]. Under-
standing the molecular mechanisms by which the various
T cell subsets are recruited to the asthmatic airway would
help design future therapeutic strategies for asthma.
Increased numbers of T cells are seen in the bronchial
mucosa of asthmatics following an allergen challenge,
and this increase in numbers has been shown to be mostly
due to recruitment from blood [12, 13]. The movement of
T cells between the vascular compartment and tissues is
carefully co-ordinated during homeostasis and in disease
through the concerted expression of adhesion molecules
and chemokine receptors [14, 15]. Chemokines, together
with their G-protein-coupled receptors, may be involved
in organ-speciﬁc homing of T cells. For example, CCR4
and CCR9 expression was shown to target T cells to the
skin and gut, respectively, in a mutually exclusive manner
[16, 17]. Human lung T cells have a unique chemokine
receptor proﬁle, which is CXCR3
high, CCR5
high, CXCR6
high,
cutaneous lymphocyte antigen (CLA)
 , and CCR9
  [18].
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restricted repertoire of chemokine receptors in vitro.T H2
cells preferentially express CCR3, CCR4 and CCR8, while
TH1 cells express CXCR3 and CCR5 [19]. Ligands for CCR3
and CCR4 have been shown to be increased within the
asthmatic airway following allergen challenge [20, 21].
However, we were unable to demonstrate a corresponding
increase of T cells expressing CCR3 or CCR4 among
bronchoalveolar lavage (BAL) T cells in stable mild asth-
matics [22]. CCR8, whose only host ligand is CCL1, is
expressed on a subset of CCR4-expressing TH2 and reg-
ulatory T cells [23, 24]. Animal models of asthma have
provided conﬂicting data on the role of CCR8 in allergic
inﬂammation. Three studies have suggested that the
receptor is not involved in mediating allergic inﬂamma-
tion in the mouse model of asthma [25–27]. However,
T cell recruitment, TH2 cytokine production and mucus
production were inhibited in CCR8-deﬁcient mice using
either a mast cell-dependent protocol or a model of fungal
asthma [28, 29]. The limited studies in humans have also
been conﬂicting. One group found exceptionally high
levels of expression of CCR8 in asthmatic sub-mucosa,
whereas another found very low levels of expression in
biopsies, with no difference from control subjects.
In contrast, using in situ hybridization, a modest increase
in the numbers of CCR4 T cells expressing CCR8 in the
bronchial mucosa of asthmatics compared with normal
subjects was observed [28, 30]. Similarly, two studies have
found an increase in CCL1 in asthma, whereas others have
not [28, 30–32].
One problem in studying CCR8 expression in human
tissue has been the paucity of good reagents. We have
used two reagents, a highly selective monoclonal anti-
body to CCR8 developed by ICOS Corporation and ﬂuor-
escently labelled CCL1 (Millennium Pharmaceuticals), to
study the involvement of CCL1 and its receptor CCR8 in
asthma. Our data support a possible role for CCR8 in the
recruitment of TH2 cells to an asthmatic lung.
Materials and methods
Subjects
Thirty-eight subjects with asthma and 22 normal controls
were included in the study. Patients were recruited from
Glenﬁeld hospital in Leicester, the United Kingdom. Sub-
jects were characterized using clinical history and lung
function. Asthma was diagnosed as described previously
[33]. Asthmatic subjects had a suggestive history with
recurrent cough, wheeze, sputum production and either
airway hyperresponsiveness [Provocatioanal concentration
that causes a 20% fall in FEV1 (Pc20)o8mg/mL] or
reversible airﬂow obstruction [forced expiratory volume
in 1s (FEV1)412%]. Normal subjects had no history of
respiratory disease. Methacholine challenge was performed
using a Wright’s nebulizer and results are expressed as the
inducing concentration of methacholine required to elicit a
20% decrease in FEV1 (Pc20). Atopic status was assessed by
measurementofthe total IgEconcentration and skin prick
tests to common aeroallergens (a weal diameter 43mm
compared with the control was deﬁned as positive). The
clinical characteristics are given in Table 1. Not all
subjects had a bronchoscopy. The clinical characteristics
of the subset of those subjects who had a bronchoscopy
are given separately with Table 1.
Allexceptsixasthmatics(mildintermittent asthma)were
using regularinhaledcorticosteroids. Eight asthmasubjects
were using oral as well as inhaled corticosteroids. Twenty
outofthe38asthmaticshadsevereasthmaaccordingtothe
British Thoracic Society criteria (steps 4 and 5). Broncho-
scopy was performed on 13 of the asthmatics and seven
normal subjects. Of the 13 asthmatics investigated with
bronchoscopy, 10 had severe asthma and of these ﬁve were
on oral corticosteroids (OCS). The study was approved by
the Leicestershire ethics committee and written informed
consent was obtained from all participants.
Bronchoscopy
Ten millilitre of venous blood was obtained before the
procedure for isolation of peripheral blood mononuclear
cells (PBMC). Bronchoscopy was performed using local
anaesthesia according to standard techniques. Asthmatic
subjects were pre-medicated with 2.5mg of nebulized
Salbutamol 20min before the procedure. Mild sedation
with midazolam was used in some subjects. BAL was
performed by sequential instillation and aspirations of
three aliquots of 60mL of warmed sterile 0.9% saline. BAL
ﬂuid was placed and transported in ice before analysis.
Biopsies were ﬁrst ﬁxed in 4% paraformaldehyde and then
embedded in parafﬁn.
Isolation of peripheral blood mononuclear cells and
bronchoalveolar lavage T cells
Ten to ﬁfteen millilitre of heparinized venous blood was
obtained from all the subjects. PBMC was isolated from
whole blood using density gradient centrifugation (Histo-
paque 1077; Sigma, Dorset, UK). PBMC were washed and
suspended in phosphate-buffered saline (PBS) (Invitrogen,
Paisley, UK)10.5% bovine serum albumin (BSA) (Sigma)
during staining and subsequent ﬂow cytometry. BAL
samples were ﬁrst ﬁltered through 48mm nylon gauze to
remove debris. Cells were pelleted and a red cell lysis was
performed if signiﬁcant blood contamination had oc-
curred. Supernatants were collected and stored at  801C
for estimation of CCL1. Red cell lysis was performed by
incubating the cellular pellet with a small volume of ice-
cold distilled water for 20s, followed by quenching with a
large volume of isotonic PBS.
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Either anti-CCR8 mAb (433H) or the ﬂuorescent-labelled
CCL1 (CCL1-F) was used to identify CCR8
1 cells. The 433H
is an unconjugated mouse IgG2a mAb directed against
human CCR8, and was a gift from ICOS Corporation
(Seattle, WA, USA). The anti-CCR8 antibody was gener-
ated by injecting mice three times intra-peritoneally with
5 10
6 COS cells, which were transfected to express high
levels of CCR8 (shown by a chemotactic response to
CCL1), suspended in an RIBI MPL1TDM adjuvant (Cor-
ixa/GSK Biologicals, Hamilton, MT, USA). Hybridoma
fusion well antibody supernatants were screened by FACS
on the CCR8 transfectants, using non-transfected cells as
the negative control. Supernatants were also tested for the
ability to block cell chemotaxis towards CCL1. Positive
wells were cloned, resulting in the identiﬁcation of
monoclonal antibody 433H. Puriﬁed 433H mAb was
shown to be speciﬁc for CCR8 by FACS and in chemotaxis
inhibition assays using a panel of cell lines transfected
with a comprehensive panel of chemokine receptors (data
not shown). The Alexa Fluor 647-labelled CCL1 (CCL1-F)
was a kind gift provided by Millennium Pharmaceuticals.
The Alexa Fluor 647 signal was detected in the FL3
channel during acquisition on the ﬂow cytometer.
Flow cytometry
This was carried out as described previously [22]. All
samples were labelled with anti-CCR8 or CCL1-F and
CD3. Anti-CD4, anti-CD8 (BD Biosciences, Oxford, UK)
and anti-CD45RO (Caltag, Buckingham, UK) were also
used in some samples. PBMC and BAL cells were incu-
bated with anti-CCR8 mAb at 41C while suspended in PBS
and 0.5% BSA. FITC or Phycoerythrin-labelled anti-
mouse, rabbit antibodies (Dako Cytomation, Cambridge,
UK) were used as the secondary antibody. Cells were
suspended in MACS buffer (Ca
21/Mg
21 Dulbecco’s phos-
phate-buffered saline and 0.5% BSA and 5mM EDTA) for
labelling with CCL1-F and this was carried out at 371C.
Intracellular cytokine was studied in some of the samples.
Where intracellular cytokine was studied, cells were first
incubated with anti-CCR8 or CCL1-F and then stimulated
using 25ng/mL of Phorbol–Myristate–Acetate (Sigma)
and 500ng/mL of Calcium Ionophore A2317 (Sigma) in
the presence of 10mg/mL Brefeldin (Sigma) for 6h at
371C. Cells were then washed and fixed using 4% Paraf-
ormaldehyde before being permeabilized with a 0.1%
solution of Saponin. Cells were then stained for intrace-
llular IL-4, IL-13 and IFN-g using directly labelled mAbs,
followed by CD3-PerCP. Samples were analysed on FACS
Canto using FACS Diva software (Becton Dickinson Im-
munocytometry system). At least 10000 live cells were
acquired from each sample for the analysis of the surface
chemokine receptor. The percentage of CD3
1 cells that
were CCR8
1 was estimated. The percentages of CD3
1 cells
that were cytokine positive were low and on average
30000–40000 PBMC and BAL cells were analysed from
each sample when intracellular cytokines were studied.
Isotype controls were included for all tests.
CCL1 quantiﬁcation
CCL1 in BAL ﬂuid was assayed using a commercially
available ELISA kit (R&D Systems Inc., Minneapolis, MN,
USA) with a detection limit of 15pg/mL. We had not been
able to detect any CCL1 in unconcentrated BAL samples
from asthmatic or normal subjects. BAL samples were
therefore 20-fold concentrated using Amicon Ultra-15
centrifugal ﬁlters (for nominal molecular weight limit
5000) (Millipore, Watford, UK). BAL samples were centri-
fuged within the centrifugation tubes at 400g for 30min
at 251C. The ﬁltrate volumes recovered were 0.25–1.0mL.
Samples were assayed by ELISA in duplicate and the
product protocol was followed. CCL1 values o15pg/mL
were considered undetectable.
Table 1. The characteristics of all asthmatics and normal subjects who were studied are given in the ﬁrst two columns
Normal Asthma Bronchoscopy normal Bronchoscopy asthma
N 22 38 7 13
Age 29 (19–56) 43 (21–61) 24 (21–49) 46 (36–60)
Male 8 21 3 5
Atopy 6 19 1 4
IgE
w (kUa/L) 17 (7.2) 525 (143) 101 (34) 277 (117)
FEV1% Pred
w 89 (5.4) 85 (3.3) 100 (6.3) 77 (5.9)
Pc20
z 416 0.5 (0.8) 416 0.9 (0.7)
On OCS 0 8 0 5
Median (range).
wMean (standard error of mean).
zGeometric mean (log SD).
The characteristics of only those who underwent bronchoscopy are given separately in the last two columns.
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T cell polarization was performed using a method adapted
from Cousins et al. [34]. In vitro polarized IFN-g
1 and
IL-4
1 T cells were expanded from PBMC isolated from
eight asthmatic subjects. CD3 cells were stimulated to
proliferate, using anti-CD3/CD28 beads (Dynabeads
s
CD3/CD28 T cell expander; Invitrogen, UK), in the pre-
sence of recombinant human IL-2. To direct in vitro
polarization towards IFN-g-producing T cells, rIL-12
(2.5ng/mL; R&D Systems) and anti-IL-4 (0.1mg/mL Pre-
proTech EC Ltd, London, UK) were added to the culture
well. To direct in vitro polarization towards IL-4-produ-
cing T cells, rhIL-4 (12.5ng/mL purchased from R&D
Systems) and anti-IFN-g antibodies (0.1mg/mL PeproTech
EC Ltd, UK) were added to the culture.
Chemotaxis assay
Chemotaxis assay was performed in a modiﬁed Boyden
chamber assay using in vitro polarized IL-4
1 T cells with
an upregulated expression of CCR8 (19–27% vs.  5% in
fresh PBMC). Migration towards recombinant human
CCL1 (R&D Systems) was assessed at a concentration of
100ng/mL diluted in RPMI 1640110% FCS. CCL1 was
placed in the lower wells of a Transwell
s chemotaxis
plate (Sigma-Aldrich, Dorset, UK). A 100mL suspension of
polarized cells at a concentration of 10 10
6/mL cells was
added to the 3mm pore size polycarbonate culture insert.
Cells pre-incubated with CCR8 mAb or the isotype IgG2A
were also included. SDF-1 (CXCL12) was used as the
positive control and a lower well without rhCCL1 was
used as the negative control. The plate was incubated at
371C for 2h in a humidiﬁed 5% CO2 incubator. Migrated
cells in the lower wells were recovered and counted at
magniﬁcation  20. Migrating cells are expressed as a
percentage of cells initially added to the culture insert.
Assays were performed in duplicate.
Immunohistochemistry and cytospins
Biopsies were ﬁxed in 4% paraformaldehyde overnight
and then embedded in parafﬁn blocks. These were then
cut to obtain 4-mm-thick sections. Antigen retrieval was
performed by immersing sections in a pH 6.0, 100mM
citrate buffer (Lab Vision, Cheshire, UK) and heating to
1201C in a pressurized container (PASCAL, Dako). CCR8
mAb and isotype control antibody was used at a concen-
tration of 10mg/mL. Biotinylated anti-mouse/anti-rabbit
IgG (H1L) was used as the secondary antibody. The
Streptavidin ABC complex was used as the detection
system. Sub-epithelium was identified morphologically.
Positive cells within the area of the sub-epithelium were
enumerated at a magnification of  400 and expressed as
number of cells per mm
2. The area covered by smooth
muscle was excluded. A minimum of 0.1mm
2 was ana-
lysed in each biopsy section. Image analysis software
(Scion Image) was used to estimate the surface area.
Statistical analysis
Subject characteristics are described using descriptive
statistics. Means are expressed together with standard
error of mean (SEM). Median values are expressed with
interquartile ranges (IQR). Statistical analysis was per-
formed with GraphPad Prism (GraphPad software Inc.).
Differences between groups were assessed using the Mann
–Whitney U-test for non-parametric and unpaired t-tests
for parametric data. Pearson’s correlation test was used to
assess the relationship between receptor expression and
clinical parameters. A P value o0.05 was considered
statistically signiﬁcant. This was an explorative study
and power calculation was not possible as the level
and variation of the expression of CCR8 are not known.
Sufﬁcient numbers of subjects were included for
the experiments on blood. The number of subjects used
for experiments with BAL were small; nevertheless, we
did detect a difference between the two populations
compared.
Results
CCR8 expression was twofold increased on in vitro
polarized IL-4
1 T cells compared with IFN-g
1 T cells in
asthma
We studied the effect of in vitro polarization to IL-4
1 and
IFN-g
1 T cells on the expression of CCR8. This allowed us
to see both whether CCR8 was preferentially associated
with IL-4
1 T cells and to test the selectivity of the new
anti-CCR8 mAb against the human CCR8 receptor in
chemotaxis assays (described below). IL-4
1 and IFN-g
1
T cells were expanded in vitro over 2 weeks from PBMC
derived from eight asthmatic donors. The mean CCR8
expression on T cells from these donors before polariza-
tion was 5.3 1.6% (Fig. 1). Expression was signiﬁcantly
increased on IL-4
1 polarized T cells (21.9 2.1%) com-
pared with IFN-g
1 polarized T cells (9.2 1.3) (Po0.01).
Previous reports of CCR8 in human asthma had been
difﬁcult to interpret due to the poor speciﬁcity of the anti-
CCR8 antibody used. We have conﬁrmed the speciﬁcity of
the 433H anti-CCR8 mAb using two methods: chemotaxis
experiments and blocking experiments using the novel
ﬂuorescence-labelled-CCL1 (CCL1-F). Chemotaxis experi-
ments were performed using IL-4
1 polarized T cells. The
mean CCR8 expression on these cells was 21.9 2.1%.
Approximately 30% of the IL-4
1 polarized T cells mi-
grated towards CCL1 compared with 10% in the control
well (Fig. 2a). This response was completely abrogated by
pre-incubation of cells with the anti-CCR8 (433H) mAb
  c 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40:1175–1185
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ments, we have pre-incubated PBMC with CCL1-F before
labelling with anti-CCR8 mAb. The CCL1-F completely
blocked the staining by anti-CCR8 (433H). Similarly, pre-
incubating PBMC with the anti-CCR8 antibody comple-
tely blocked the binding of CCL1-F to the CCR8 receptor
(Fig. 2b).
There were more CCR8
1 T cells in the blood from subjects
with asthma compared with normal controls
CCR8 expression among blood T cells was conﬁned to a
small percentage of T cells in both asthmatic and normal
subjects (normal controls 3.0 0.4% and asthmatics
4.7 0.4%). The percentage of CCR8
1 T cells was signiﬁ-
cantly higher in asthmatic subjects compared with normal
controls (Po0.01) (Fig. 3). CCR8 expression was mostly
conﬁned to CD3
1 cells among the PBMC population. The
majority of CCR8
1 Tcells were CD45R0
1 (77 4.3%; n=3)
and CD4
1 T cells (82.3 2.8; n=6).15 2.1% of CD8
1 T
cells expressed CCR8 (n=6). We had also explored
whether there was any association of CCR8 expression
with serum markers of allergy (IgE and eosinophils) in
both asthmatics and normal controls. There was no
signiﬁcant association between the percentage of CCR8
1
T cells and serum IgE (r
2=0.14; P=0.4) or blood eosino-
phil count (r
2=0.267; P=0.09).
CCR8 expression was enriched on IL-4
1/IL-13
1 T cells
compared with IFN-g
1 T cells in blood from asthma and
normal subjects
We studied the association of CCR8 with IL-4
1 T cells by
analysing their expression on IFN-g
1, IL-4
1 and IL-13
1 T
cells following in vitro stimulation with PMA and calcium
ionophore. We conﬁrmed that stimulation did not affect
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Fig. 2. (a) Chemotaxis of in vitro polarized IL-4
1 cells towards rhCCL1.
SDF-1 was used as the positive control. Migration towards CCL1 was
blocked by pre-incubating cells with anti-CCR8 mAb (433H). Graph
shows data from six different experiments. Columns represent mean
percentages and error bars standard error of mean. Po0.05 using the
Mann–Whitney test. (b) Representative FACS plot showing the binding of
anti-CCR8 mAb being blocked by Alexaﬂuor 647-labelled CCL1 (CCL1-
F). (A) Cells are incubated with CCR8 mAb (433H) and then CCL1-F.
(B) Cells are incubated with CCL1-F ﬁrst and then CCR8 mAb.
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Fig. 1. T cell CCR8 expression among fresh peripheral blood mono-
nuclear cells (PBMC), in vitro polarized IFN-g
1 and IL-4
1 cells. Graph
shows data from eight different experiments using PBMC from eight
different asthmatic subjects. Bars represent median percentages.
(Po0.01 using the Mann–Whitney test).
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asthma, 29.8 3.5% and 36 3.5% of the IL-4
1 and IL-
13
1 blood T cells expressed CCR8 while only 4.3 1.0% of
IFN-g
1 cells expressed CCR8 (Po0.001) (Fig. 4a).
A similar degree of enrichment of CCR8
1 cells on IL-4
1
and IL-13
1 T cells relative to IFN-g
1 T cells was seen in
the blood from normal subjects (Fig. 4b).
There were more CCR8
1 T cells in the bronchoalveolar
lavage of asthmatics compared with normal subjects
Previous ﬂow cytometry-based studies of CCR in BAL
have shown higher percentages of CCR4, CCR2, CCR6 and
CXCR6 in the lung compared with blood CD3
1 cells;
however, none have shown a difference between asth-
matic and normal controls. Studies of CCR8 expression on
BAL cells have been limited by the lack of availability of a
reliable antibody. We studied BAL samples from 13 asth-
matics and seven normal subjects for CCR8 expression.
There were signiﬁcantly more CCR8-expressing T cells in
BAL from asthmatics compared with normal controls
(mean percentage 8.6 0.8% and 3.9 0.7%, respectively)
(Po0.01) (Fig. 5a). There was also a signiﬁcant increase in
the percentage of CCR8
1 T cells in BAL compared with
blood within the same subject in asthmatics (9.03 0.9%
vs. 5.69 0.94%) (Po0.01). This was not observed in
normal subjects (Figs 5a and b).
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Fig. 3. Scatter plot of CCR8 expression on blood T cells in asthmatics (m)
and normal subjects ( ). Po0.01 using the Mann–Whitney test. Bars
represent the mean percentages.
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Fig. 4. (a) Scatter plot of CCR8 expression on IFN-g
1 (^), IL-4
1 ( ) and
IL-13
1 (m) peripheral blood mononuclear cells (PBMC) derived CD3
1
cells from asthmatic subjects. Cells were incubated with PMA and
calcium ionophore for 6h before staining with anti-IFN-g, anti-IL-4 or
anti-IL-13. Po0.001 using the Mann–Whitney test. Bars represent
mean percentages. (b) Scatter plot of CCR8 expression on IFN-g
1 (^), IL-
4
1 ( ) and IL-13
1 (m) PBMC-derived CD3
1 cells from normal subjects.
Cells were incubated with PMA and calcium ionophore for 6h before
staining with anti-IFN-g, anti-IL-4 or anti-IL-13. Po0.001 using the
Mann–Whitney test. Bars represent the mean percentages.
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1180 K. Mutalithas et alCCR8 is preferentially expressed on IL-4
1 T cells in
bronchoalveolar lavage
As with blood T cells, CCR8 was enriched on IL-4
1 T cells
in BAL. In asthma, CCR8 was expressed by 30.3 3.0% and
28.9 7.8% of the IL-4
1- and IL-13
1-producing BAL
CD3
1 cells, respectively. In contrast, only 4.9 2.0% of
IFN-g
1 BAL CD3
1 cells expressed CCR8 (Fig. 6a).
A similar pattern of CCR8 expression was seen on IL-4
1-
and IL-13
1-producing BAL T cells from normal subjects
(Fig. 6b).
There was a higher concentration of CCL1 in
bronchoalveolar lavage of asthmatics compared with
normal controls
We found a higher percentage of CCR8
1 Tcells in the BAL
of asthmatic subjects compared with normal controls. We
investigated whether the ligand for CCR8 (CCL1) was
present in increased concentrations in the BAL ﬂuid of
asthmatics compared with normal controls. Preliminary
studies showed that CCL1 was not detectable in BAL ﬂuid
but was detectable following concentration. We used
ultracentrifugation ﬁlters to concentrate BAL ﬂuid sam-
ples 20-fold. The mean concentration of CCL1 in 20  BAL
ﬂuid from asthmatic subjects was signiﬁcantly higher
than in that in normal subjects (35 6 vs. 12.9 7pg/mL;
Po0.05) (Fig. 7).
There were more CCR8-positive cells in bronchial biopsies
from asthmatic compared with normal subjects
In addition to blood and BAL ﬂuid, we also investigated
the presence of CCR8
1 Tcells within the bronchial mucosa
of asthmatic and normal subjects. Biopsies were obtained
from ﬁve normal and eight severe asthmatics. The 433H
anti-CCR8 mAb only showed staining in parafﬁn-
embedded specimens. The thickness of sections produced
using parafﬁn-embedded specimens did not allow accu-
rate co-localization of CD3
1 and CCR8
1 cells. Most, if not
all, blood CCR8
1 were CD3
1 on ﬂow cytometry studies,
and so those cells that were CCR8
1 are probably all Tcells.
The mean SEM of CCR8
1 cells seen within the sub-
epithelium of the bronchial biopsies taken from asth-
matics was 93 11cells/mm
2 compared with 31 16cells/
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2 in normal subjects (Po0.05) (Figs 8a–c). CCR8
1
cells were seen mostly intra-epithelium and in the sub-
epithelium.
Discussion
In this study, we have shown for the ﬁrst time that there
are increased numbers of CCR8
1 T cells in the BAL of
asthmatics compared with normal subjects. Moreover, in
paired blood and BALsamples from asthmatics, there were
more CCR8-expressing T cells in BAL than in blood. This
difference could be due to the recruitment of CCR8-
expressing T cells from blood to the lung, a possibility
supported by the increased concentration of CCL1 in BAL
ﬂuid from asthmatics compared with normal subjects.
This study therefore provides further evidence for a
potential role for CCR8 in lung T cell recruitment in
clinical asthma.
The investigation of the role of CCR8 in human disease
has been hampered by the lack of robust reagents to detect
CCR8 expression on the cell surface. We have for example
been unable to obtain reliable staining with the two
commercially available anti-CCR8 antibodies (data not
shown). For this study, we had access to a well-character-
ized, speciﬁc, blocking, monoclonal antibody from ICOS
Corporation, which could be used in both ﬂow cytometry
and immunohistochemistry. We also found that this anti-
body showed good speciﬁcity for the CCR8 receptor. In
chemotaxis assays using in vitro polarized IL-4
1 cells, we
found that the antibody effectively inhibited CCL1-
mediated T cell migration. In addition, CCL1-F yielded
the same amount of staining for CCR8 as the anti-CCR8
antibody and pre-incubation with the labelled CCL1
blocked subsequent binding of the anti-CCR8 antibody to
T cells. Similarly, the anti-CCR8 antibody also effectively
blocked binding of the CCL1-F to CCR8. We are therefore
conﬁdent that this antibody recognizes human CCR8.
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studies of CCR8 expression by TH2 cells. After 2 weeks of
in vitro culture under TH2 polarizing conditions, the
percentage of CD3
1 cells expressing CCR8 was signiﬁ-
cantly increased compared with that cultured under TH1
polarizing conditions. We have also demonstrated the
association of CCR8 expression with IL-4
1 T cells ex vivo
using blood and BAL T cells by simultaneous intracellular
cytokine and surface CCR8 measurement. There was an
approximately sixfold enrichment of CCR8 expression on
IL-4
1 T cells compared with IFN-g
1 T cells. We acknowl-
edge that the percentages of IL-4
1/IL-13
1 T cells in our
study also included CD8
1 T cells (Tc2). Furthermore, cells
in our study were single stained with anti-IL-4 or anti-
IFN-g, and some of the IL-4
1 T cells may also be IFN-g
1
(TH0 cells). This would also apply to the in vitro polarized
T cells. Given these limitations, we would not be able to
suggest a deﬁnite association of CCR8 with TH2 cells using
our data. Nevertheless, CCR8 expression was seen on a
signiﬁcantly higher percentage of IL-4
1 and IL-13
1
T cells compared with IFN-g
1 T cells among blood and
BAL T cells in both asthmatics and normal subjects.
Our ﬁndings on the expression of CCR8 on peripheral
blood cells were similar to the recently reported ﬁndings
of Soler et al. [24], who used CCL1-F to identify CCR8-
expressing cells in human peripheral blood. They noted a
predominant expression on CD4
1CD45RO
1 T cells, with
an approximately sixfold enhancement of expression on
TH2-cytokine producing Tcells. They also found increased
expression of CCR8 on FOXP3-expressing Treg cells,
accounting for  60% of this group of Treg cells. Among
CCR8
1 T cells,  20% were shown to express FOXP3. In
this study, we had noted a signiﬁcantly higher percentage
of CCR8 expression on peripheral blood T cells from
asthmatics, which has not been observed for any other
chemokine receptors. There was no statistical difference
between the expression ofCCR8 among PBMC from severe
compared with mild-moderate asthmatics (mean percen-
tages of 5.2 vs. 4.1).
Our most striking ﬁnding was the greater percentage of
BAL T cells expressing CCR8 in asthmatics compared with
normal controls. Previous studies have demonstrated
higher percentages of CCR2, CCR4, CCR5, CCR6, CXCR3
and CXCR6 among lung T cells compared with blood.
However, there was no difference in any of the T cell-
expressed chemokine receptors between asthmatics and
normal subjects including the TH2 cell-associated recep-
tors CCR3 and CCR4, and so what we have observed
appears to be speciﬁc for CCR8 [18, 22, 35, 36]. This may
be because previous studies of chemokine receptor ex-
pression in asthma have been on mild steroid naı ¨ve
asthmatics, whereas our subjects, who underwent
bronchoscopy, had more severe disease. Unlike our
previous studies, we did ﬁnd a signiﬁcant although
modest twofold increase in the percentage of IL-4/IL13-
expressing BAL T cells in the asthmatics compared with
the healthy subjects (data not shown), which would be
consistent with the approximately twofold increase in the
percentage of CCR8-expressing cells. It is always possible
that the increased expression of CCR8 compared with
normal subjects was due to treatment, in particular
steroids. However, as we found no difference in the
expression of CCR8 in blood or BAL in patients taking
oral steroids vs. those only on inhaled steroids, we feel this
is unlikely.
It is not possible to say whether the increased CCR8
expression was due to the activation of BAL T cells or
increased recruitment of CCR8-expressing Tcells from the
blood. However, in support of the latter mechanism, we
did observe an increase in the CCL1 concentrations in BAL
ﬂuid. This was at low concentrations, well below the
amount required for chemotaxis. However, it is difﬁcult
to extrapolate from concentration in BAL the site of
release and action in the lung. One other group has also
reported increased CCL1 in BAL ﬂuid in asthmatics,
although another group was not able to detect CCL1 in
allergen-challenged asthmatics [31, 32]. CCL1 was not
detected in bronchial biopsies following an allergen
challenge in one study [21]. However, increased expres-
sion of CCL-1 was observed by in situ hybridization by
another group [28]. There have also been reports of CCL-
17 (found at higher levels in asthma BAL compared with
normal controls) being a ligand for CCR8, although this
observation was not supported by another group [37, 38].
The extent to which there is a chemotactic signal for
CCR8
1 cells in asthmatic airways therefore needs further
investigation.
Three reports have been published of CCR8 expression
in the airways in asthma, all studying bronchial biopsies
[21, 28, 30]. In the ﬁrst of these reports, CCR8 expression
was studied using a goat polyclonal antibody raised
against an extracellular peptide in bronchial biopsies after
allergen challenge [21]. In excess of 250 CCR8
1 T cells/
mm
2 were detected at baseline and a mean of 1000 after
allergen challenge. In contrast, a second study, also using
a goat polyclonal antibody from the same company,found
just 4cells/mm
2 staining positive for CCR8 in the mucosa
of moderate to severe asthmatics and no difference from
controls [30].
A third study studied CCR8 mRNA in bronchial biopsies
using in situ hybridization [28]. Ten asthmatics were
compared with seven normal controls. Increased CCR8
mRNA was shown in the asthmatic biopsies compared
with normal controls (27.3 vs. 7.4cells/mm
2), the majority
of which were CD4 Tcells. Our study supports the ﬁndings
of this study, although we found higher numbers of
positive cells in the mucosa. The study by Gonzalo and
colleagues had also shown increased staining for CCL1 in
the bronchial biopsies of asthmatics. Interestingly, they
had also shown that CCL1 was the major chemokine
  c 2010 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 40:1175–1185
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A mast cell-driven recruitment of TH2 cells to the asth-
matic airway was proposed by Gonzalo et al. [28].
The exact contribution made by CCR8-expressing
T cells would need further detailed study, especially so
with the development of CCR8 antagonists that may have
potential clinical use [39]. Current evidence suggests that
CCR8-expressing T cells may have multiple roles. It is
possible that a signiﬁcant proportion of CCR8-expressing
cells are Tregs and CCR8 may play a role in the trafﬁcking
of these cells [24, 40]. However, given their inhibitory
effect on immune processes including TH2 cells [41], one
would expect their numbers to be decreased in asthma. On
the other hand, the percentage of Treg cells in blood is
known to be increased with the use of inhaled and oral
glucocorticoids [42]. All patients who had participated in
the bronchoscopic part of the study were taking high
doses of inhaled steroids and some were also taking OCS.
CCR8 may act in concert with other chemokine recep-
tors in guiding certain T cell subsets to tissue sites. CCR8
1
cells that also expressed CLA were shown to have equal
frequencies of TH1 and TH2 cells, whereas TH2 cells were
several folds enriched in the CLA
  CCR8
1 population,
suggesting that CCR8 may be one of a combination of
receptors guiding TH2 cells to disease sites [24]. Our study
provides evidence that CCR8 may be involved in human
asthma and may contribute to its pathogenesis in part
through its role in trafﬁcking TH2 cells to the lung. CCR8
may potentially be an important target for therapeutic
intervention.
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